Fortis Healthcare growth supported by brownfield beds, richer case mix and Agilus revival

Investment View and Legal Overhang

Motilal Oswal Financial Services published this Fortis Healthcare update on September 4, 2026. The broker maintains its Buy rating and values Fortis Healthcare at Rs 1,130 per share on a sum-of-the-parts basis.

The investment thesis rests on volume-led hospital growth, brownfield bed expansion, an improving case and payer mix, migration of facilities towards higher profitability bands and a recovery in the Agilus diagnostics business.

• The Delhi High Court has directed a forensic audit into alleged historical asset dissipation by Fortis Healthcare's former promoters.
• The inquiry will reconstruct transactions involving the former promoters' shareholding, the subsequent change in control and the roles of relevant persons, companies, banks and financial institutions.
• It will also examine IHH's stake acquisition, although IHH was not party to the execution proceedings against the former promoters.
• Motilal Oswal expects the audit process to take around six months.

Fortis Healthcare continues to evaluate strategic and operating actions to drive earnings growth and stakeholder value. Motilal Oswal's view is that operational performance remains intact despite the legal overhang.

Hospital Business: Volume Growth and Capacity Expansion

Hospitals contribute about 85 per cent of consolidated revenue and remain the principal earnings driver. Hospital revenue rose about 19 per cent year on year in Q1 FY27, compared with a 15 per cent CAGR over FY23 to FY26.

The broker attributes Q1 FY27 growth primarily to an implied 15-16 per cent increase in volumes, supported by more occupied beds and improved realisations. Fortis Healthcare maintained occupancy of 68-69 per cent despite a 17 per cent increase in operating beds over the preceding year. Operating beds stood at 4,940 in Q1 FY27.

Management plans to add around 2,000 brownfield beds over four years, including around 500 beds in FY27, providing capacity for continued volume growth. Motilal Oswal expects hospital revenue to grow at a 13 per cent CAGR over FY26 to FY28.

Case Mix, ARPOB and Specialty Trends

Management targets average revenue per occupied bed, or ARPOB, growth of around 4-5 per cent over the next two years, with approximately half from pricing and the balance from case-mix improvement.

Cardiac surgery's share of inpatient revenue declined from 18.6 per cent in FY23 to 16.6 per cent in Q1 FY27 as orthopaedic and neurology specialties gained traction. Robotics, radiation and other complex procedures could support a higher-acuity mix and ARPOB.

Oncology growth moderated to around 5 per cent in Q1 FY27 from around 23-24 per cent earlier because of chemotherapy-drug pricing for ECHS and CGHS patients. Management expects oncology growth to recover to around 10-12 per cent.

Margin Migration and Hospital Productivity

The more than 20 per cent EBITDA-margin hospital cohort generated around 70 per cent of hospital revenue from around 65 per cent of beds, reflecting mature-asset productivity.

The 15-20 per cent margin cohort generated Rs 4,000 million of revenue in Q1 FY27, up 74.8 per cent year on year, and could benefit from occupancy improvement and operating leverage. Management sees 200-300 basis points of occupancy headroom at 10-20 per cent margin hospitals.

Lower-margin facilities are shrinking in significance. Manesar and Greater Noida are targeted to reach mid-teens margins by end-FY27.

Diagnostics: Agilus Recovery

Diagnostics contributes around 15 per cent of consolidated revenue. Agilus revenue grew 10.3 per cent year on year to Rs 4,100 million in Q1 FY27, ahead of the roughly 4 per cent revenue CAGR over FY23 to FY26.

Under new leadership led by Vijender Singh, management is seeking to accelerate recovery after network rationalisation. Improved NCR performance could extend to other regions. Q1 FY27 diagnostic EBITDA margin was 23.8 per cent, supported by mix and realisations.

In Q1 FY27, tests were 10 million, patients were 4 million, average revenue per test was Rs 387 and average revenue per patient was Rs 952.

The broker expects diagnostics revenue and EBITDA CAGRs of 10 per cent and 12 per cent, respectively, over FY26 to FY28. Growth is expected to be supported by more customer touchpoints, greater sample volumes, a shift towards business-to-consumer and a broader test menu.

Financial Forecasts and Valuation

EBITDA margin is projected to rise from 22.8 per cent in FY26 to 24.6 per cent in FY28E. The broker applies 30 times 12-month forward enterprise value to EBITDA to the hospital business and 23 times to diagnostics to derive its Rs 1,130 target price.

Key Factors to Monitor

• The forensic-audit overhang and its implications.
• Oncology pricing pressure.
• Successful execution of planned bed additions.
• Occupancy ramp-up at lower- and mid-margin hospitals.
• Margin migration at facilities including Manesar and Greater Noida.
• The pace of Agilus recovery.